Africa’s one-dose cure brings sleeping sickness elimination within reach
AFRICA’S long battle against sleeping sickness may be approaching its final chapter as a new single-dose therapy gains international regulatory backing. The drug, acoziborole, received a positive scientific opinion on 27 February 2026 from the Committee for Medicinal Products for Human Use of the European Medicines Agency, clearing the way for national approval processes in countries where the disease remains endemic. The decision was issued under the EU-M4all programme, a regulatory pathway designed to accelerate access to medicines intended primarily for use outside the European Union. Under this procedure, scientific assessment by European regulators supports approvals in countries facing major…
